The 2022 European Heart Rhythm Association consensus recommends that the initial pool of genes to be tested for DCM should include genes with definitive evidence of pathogenicity, and may already include genes with moderate evidence of pathogenicity: this includes the genes BAG3, DES, FLNC, LMNA, MYH7, PLN, RBM20, SCN5A, TNNC1, TNNT2, TTN, DSP and the genes ACTC1, ACTN2, JPH2, NEXN, TNNI3, TPM1, VCL, respectively [55]. This evidence concerns the gene TTN and familial dilated cardiomyopathy.